CGEM
NASDAQ · Biotechnology
Cullinan Therapeutics Inc
$21.36
+0.01 (+0.05%)
Open$21.35
Previous Close$21.35
Day High$21.89
Day Low$21.28
52W High$23.19
52W Low$5.68
Volume—
Avg Volume927.7K
Market Cap1.35B
P/E Ratio—
EPS$-3.41
SectorBiotechnology
Analyst Ratings
Strong Buy
19 analysts
Price Target
+0.4% upside
Current
$21.36
$21.36
Target
$21.45
$21.45
$16.94
$21.45 avg
$32.37
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 156.49M | 140.29M | 129.25M |
| Net Income | -25,188,754 | -25,282,384 | -20,083,076 |
| Profit Margin | -16.1% | -18.0% | -15.5% |
| EBITDA | -32,256,643 | -27,830,603 | -25,262,091 |
| Free Cash Flow | -9,992,952 | -10,952,071 | -13,180,515 |
| Rev Growth | +6.1% | +12.8% | -3.3% |
| Debt/Equity | 0.08 | 0.08 | 0.10 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $265.21 | +0.28% | 74.0 | 466.74B |
| AMGN | Amgen Inc | $410.24 | +4.34% | 23.7 | 207.25B |
| GILD | Gilead Sciences Inc | $152.67 | +1.40% | — | 187.10B |
| VRTX | Vertex Pharmaceuticals Inc | $514.99 | +0.84% | 29.7 | 130.64B |
| REGN | Regeneron Pharmaceuticals | $803.90 | +0.72% | 18.6 | 80.58B |
| ALNY | Alnylam Pharmaceuticals Inc | $251.65 | +3.00% | 40.0 | 32.33B |